Table 2.
Univariate and multivariate Cox proportional hazard regression analyses of CSS
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Gender, female | 1.07 (0.43–2.66) | 0.878 | ||
| Age (years) | 0.99 (0.95–1.03) | 0.620 | ||
| Tumour size (cm) | 1.06 (0.95–1.18) | 0.323 | ||
| Thrombus level | ||||
| I | Ref. | |||
| II | 1.09 (0.37–3.15) | 0.881 | ||
| III | 1.83 (0.61–5.46) | 0.280 | ||
| IV | 0.57 (0.07–4.73) | 0.601 | ||
| Blood transfusion (103 cc) | 1.36 (1.06–1.76) | 0.017 | 1.34 (1.01–1.77) | 0.041 |
| Lymph node involvement | 1.96 (0.58–6.67) | 0.279 | ||
| Metastasis | 2.88 (1.24–6.70) | 0.014 | 3.87 (1.56–9.61) | 0.004 |
| Histologic subtype | ||||
| Clear cell RCC | Ref. | |||
| Non-clear cell RCC | 1.87 (0.72–4.85) | 0.196 | ||
| Sarcomatoid differentiation | 3.54 (1.34–9.38) | 0.011 | 3.90 (1.42–10.71) | 0.008 |
| Rhabdoid differentiation | 3.82 (1.39–10.51) | 0.009 | 3.01 (1.04–8.74) | 0.042 |
| Fuhrman grade | ||||
| 1–2 | Ref. | |||
| 3–4 | 1.47 (0.57–3.76) | 0.423 | ||
| Tumour necrosis | 1.78 (0.75–4.24) | 0.191 | ||
| Adjuvant target therapy | 0.55 (0.23–1.36) | 0.199 | ||
CSS cancer specific survival, RCC renal cell carcinoma